Liste des publications GINECO - Ovaire

Par le biais de cette page, vous pouvez accéder à la liste des publications, abstract et poster du GINECO.

Liste des publications - Ovaire

Publications Ovaire 2014

  • AGO-OVAR16/VEG110655 – Article - Original Report (Journal of Clinical Oncology)
    A. du Bois
    Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer.
    Journal of Clinical Oncology - Septembre 2014 (réf. PubMed : PMID : 25225436 [PubMed - as supplied by publisher] )
  • AGO-OVAR16/VEG110655 – Article - Editorial (Journal of Clinical Oncology)
    KE. Oliver
    Ovarian Cancer and Antiangiogenic Therapy: Caveat Emptor.
    Journal of Clinical Oncology - Septembre 2014 (réf. PubMed : PMID : 25225422 [PubMed - as supplied by publisher] )
  • Calypso – Article (Gynecologic Oncology)
    M. Wilbaux
    Dynamic modeling in ovarian cancer: An original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development.
    Gynecologic Oncology - Avril2014 (réf. PubMed : PMID: 24726614 [PubMed - as supplied by publisher] )
  • Calypso – Article (British Journal of Cancer)
    M. Wilbaux
    Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients.
    British Journal of Cancer - Mars 2014 (réf. PubMed : PMID: 24556626 [PubMed - in process] - PMCID: PMC3960627 [Available on 2015/3/18] )
  • Aurelia – Article (Journal of Clinical Oncology)
    E. Pujade-Lauraine
    Original Reports - Rapid Communications: Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial.
    Journal of Clinical Oncology - Mars 2014 (réf. PubMed : PMID: 24637997 [PubMed - in process] )
  • Aurelia – Article (Journal of Clinical Oncology)
    M. R. Stockler
    Original Reports - Gynecologic Cancer: Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer.
    Journal of Clinical Oncology - Mars 2014 (réf. PubMed : PMID: 24687829 [PubMed - in process] )
  • MITO7 – Article (The Lancet Oncology)
    S. Pignata
    Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    The Lancet Oncology - Février 2014 (réf. PubMed : PMID: 24582486 [PubMed - as supplied by publisher] )

Publications Ovaire 2013

  • Calypso – Article (Gynecologic Oncology)
    B. You
    The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study).
    Gynecologic Oncology - Août 2013 (réf. PubMed : PMID: 23694718 [PubMed - indexed for MEDLINE] )
  • FAG3 – Article (Annals of Oncology)
    C. Falandry
    Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial.
    Annals of Oncology - Novembre 2013 (réf. PMID: 24061628 [PubMed - in process] )
  • OCTAVIA – Article (European Journal of Cancer)
    A. Gonzalez-Martin
    Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
    European Journal of Cancer - Septembre 2013 (réf. PMID: 24007819 [PubMed - as supplied by publisher] )
  • ETAMINE – Article (Support Care Cancer)
    B. Weber
    A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.
    Support Care Cancer - Juillet 2013 (réf. PubMed : PMID: 23420555 [PubMed - in process])
  • ICON7 – Article (The Lancet Oncology)
    D. Stark
    Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
    The Lancet Oncology - Mars 2013 (réf. PubMed : PMID: 23333117 [PubMed - in process])

Publications Ovaire 2012

  • Aurelia – Article (Journal of Clinical Oncology)
    B.J. Roth
    Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
    Annals of Oncology - Décembre 2012 (réf. PubMed : PMID: 23213095 [PubMed - as supplied by publisher])
  • Calypso – Article (Annals of Oncology)
    C. K. Lee
    A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
    Annals of Oncology - Octobre 2012 (réf. PubMed : PMID: 23104722 [PubMed - as supplied by publisher])
  • Calypso – Article (British Journal of Cancer)
    U. Wagner
    Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
    British Journal of Cancer - Août 2012 (réf. PubMed : PMID: 22836511 [PubMed - in process])
  • CalypsoArticle (British Journal of Cancer)
    J. Alexandre
    CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.
    British Journal of Cancer - Février 2012 (réf. PubMed : PMID: 22240800 [PubMed - indexed for MEDLINE] PMCID: PMC3322951 [Available on 2013/2/14])
  • CalypsoArticle (Annals of Oncology)
    M. Brundage
    Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.
    Annals of Oncology - Janvier 2012 (réf. PubMed : PMID: 22291207 [PubMed - in process])

Publications Ovaire 2011

  • CalypsoArticle (Annals of Oncology)
    L. Gladieff
    Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
    Gynecologic Oncology - Octobre 2011 (réf. PubMed : PMID: 21976386 [PubMed - in process])
  • CalypsoArticle (British Journal of Cancer)
    C. K. Lee
    Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
    British Journal of Cancer - Juillet 2011 (réf. PubMed : PMID: 21750553 [PubMed - indexed for MEDLINE] - PMCID: PMC3172911 [Available on 2012/7/26])
  • CalypsoArticle (Journal of the National Cancer Institute)
    C. K. Lee
    Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer
    Annals of Oncology - 11 Août 2011 (réf. PubMed : PMID: 21840849 [PubMed - indexed for MEDLINE])
  • CalypsoArticle (British Journal of Cancer)
    C. K. Lee
    Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.
    British Journal of Cancer - Octobre 2011 (réf. PubMed : PMID: 21915127 [PubMed - indexed for MEDLINE] - PMCID: PMC3208495 [Available on 2012/10/11])
  • CalypsoArticle (Gynecologic Oncology)
    F. Joly
    Decreased hypersensitivity reactions with carboplatin pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial
    Gynecologic Oncology - Août 2011 (réf. PubMed : PMID: 21575983 [PubMed - indexed for MEDLINE])
  • CalypsoArticle (Annals of Oncology)
    J. E. Kurtz
    Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
    Annals of Oncology - 14 Mars 2011 (réf. PubMed : PMID: 21402619 [PubMed - indexed for MEDLINE])
  • CartaxhyArticle (Annals of Oncology)
    A. Lortholary
    Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)
    Annals of Oncology - 11 Mai 2011 (réf. PubMed : PMID: 21562072 [PubMed - as supplied by publisher])

Publications Ovaire 2010

  • CalypsoArticle (Journal of Clinical Oncology)
    E. Pujade-Lauraine
    Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
    Journal of Clinical Oncology - Juillet 2010 (réf. PubMed : PMID: 20498395 [PubMed - indexed for MEDLINE])
  • TMROArticle (Bulletin du Cancer)
    I. Ray-Coquard
    Les tumeurs rares de l'ovaire : stratégies thérapeutiques en 2010, Observatoire francophone des tumeurs rares de l'ovaire et émergence des centres de références Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of réf.erent centers in France
    Bulletin du Cancer - Société Française du Cancer - Janvier 2010 (réf. : Volume 97 • N° 1 • janvier 2010)
  • TCGArticle (Journal of Clinical Oncology)
    A. du Bois
    Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer.
    Journal of Clinical Oncology – 2010 (Published Ahead of Print on August 23, 2010 as 10.1200/JCO.2009.27.4696)

Publications Ovaire 2009

  • CartaxhyPoster – 4,87 Mo
    L. Gladieff
    Monotherapy versus doublet in resistant ovarian cancer: a randomised phase II gineco trial (cartaxhy)
    ASCO 2009 (article sous presse) – 2009
  • TCGAbstract – 46 ko
    AC. Hardy-Bessard
    Final results of the GCIG phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-Paclitaxel-Carboplatin versus Paclitaxel-Carboplatin as First-line Treatment of Ovarian Cancer
    ESGO 2009 (article sous presse) – 2009
  • TCGAbstract – 46 ko
    J. Herrstedt
    A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as firstline treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients
    ESGO 2009 (article sous presse) – 2009
  • PACAArticle (Anticancer Research)
    B. Weber
    Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.
    Anticancer Research - Novembre 2009 (réf. PubMed : PMID: 19846972 [PubMed - indexed for MEDLINE] - Anticancer Res. 2009 Oct;29(10):4195-200)
  • ElogemArticle (British Journal of Cancer) ou Article (PubMed Central)
    I. Ray-Coquard
    Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
    British Journal of Cancer – Février 2009 (réf. PubMed : PMID: 19190632 [PubMed - indexed for MEDLINE] - PMCID: PMC2653739 -
    Br J Cancer. 2009 Feb 24;100(4):601-7. doi: 10.1038/sj.bjc.6604878. Epub 2009 Feb 3.)

Publications Ovaire 2008

  • HerceptinArticle (Clinical Ovarian Cancer)
    I. Ray-Coquard
    HER2 Overexpression/Amplifi cation and Trastuzumab Treatment in Advanced Ovarian Cancer: A GINECO Phase II Study
    Clinical Ovarian Cancer – Juin 2008

Haut de page


Mise à jour 06/09/2011


icone ARCAGY - GINECO Bookmark and Share imprimante [Imprimer la page] - Association ARCAGY - GINECO - Hôpital Hôtel Dieu